Lung cancer among nonsmokers is associated with germline risk factors, and EGFR/ALK-targeted therapies provide substantial ...

Akeso (9926.HK) is excited to announce that the significant results from the final overall survival analysis of the Phase III HARMONi-A study, which evaluates the first-in-class bispecific antibody ...

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling ...

Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...

Although several novel agents are on the horizon, including next-generation tyrosine kinase inhibitors for tertiary mutations ...

A phase 2 clinical study (NCT03974022)found that sunvozertinib (Zegfrovy) was efficacious in 2 different doses, but ...

Sacituzumab tirumotecan significantly reduced progression or death risk by 51% compared to chemotherapy in EGFR-mutated non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. The ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

A lung cancer diagnosis can feel frightening. And when a family member is diagnosed, you might wonder about your own risk, prompting you to ask if lung cancer is hereditary. Smoking tobacco accounts ...